Second primary cancers and hormonal therapies for prostate cancer: A nested case–control study
Fundamental & Clinical Pharmacology · 2025
DOI: 10.1111/fcp.70004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Lucie-Marie Scailteux und 6 weiteren Autor:innen. Beteiligte Einrichtung: Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoplasms, Second Primary, Phenylthiohydantoin, Androgen Antagonists. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de Sécurité du Médicament et des Produits de Santé.
Abstract (Originalsprache)
Introduction
(Pre‐)clinical studies have not ruled out a potential risk of second primary cancer (SCP) under the effect of some new androgen receptor pathway inhibitors (ARPIs), especially enzalutamide (ENZ).
Methods
Using the French health reimbursement claims database (Système National des Données de Santé), we designed a case–control study nested in a 2013–2020 cohort of new users of androgen‐deprivation therapy. The cases were patients with a first diagnosis of SPC, identified beyond 12 months following cohort entry and up to December 31st , 2021; up to 10 controls were matched per case, based on age and cohort entry date. The main analysis focused on patients who had not switched to a different ARPI. Applying a one‐year lag time, we determined the most frequent and longest cumulative exposure patterns to abiraterone (ABI) or ENZ and estimated the odds ratios.
Results
The cohort comprised 147 092 patients, including 7928 cases and 78 554 controls eligible for analysis. The SPCs mainly involve the digestive organs, the urinary tract, or the lungs. Recent and short exposure to ENZ was associated with SPC: OR 1.7, 95% CI [1.2–2.4]. Recent one full year of exposure to ABI, as well as full‐year plus part of the second year, was associated with SPC: OR 1.8 [1.2–2.7] and 2.3 [1.3–4.0], respectively. Discussion/Conclusion SPC cases were mainly observed among recently exposed patients, which could be linked to a detection bias. The insufficient number of patients exposed over many years means that no definitive conclusions can be drawn.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.
- Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre, Rennes University Hospital, Rennes, France.
- Service de Pharmacologie Médicale, CHU Bordeaux ; Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, Inserm, DRUGS-SAFE National Platform of Pharmacoepidemiology, University of Bordeaux, Bo…
- Department of Medical Oncology, CLCC Eugène Marquis, COSS (Chemistry Oncogenesis Signaling), INSERM, University Rennes, Rennes, France.
ORCID-Profile: Lucie-Marie Scailteux
Förderung
- Agence Nationale de Sécurité du Médicament et des Produits de Santé
Zitieren
APA
Scailteux, L. M., Bezin, J., Gundelwein, M., Edeline, J., Oger, E., Balusson, F., & Pariente, A. (2025). Second primary cancers and hormonal therapies for prostate cancer: A nested case–control study. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70004
Vancouver
Scailteux LM, Bezin J, Gundelwein M, Edeline J, Oger E, Balusson F, et al. Second primary cancers and hormonal therapies for prostate cancer: A nested case–control study. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.70004
BibTeX
@article{Scailteux2025,
author = {Scailteux, Lucie-Marie and Bezin, Julien and Gundelwein, Marion and Edeline, Julien and Oger, Emmanuel and Balusson, Frédéric and Pariente, Antoine},
title = {Second primary cancers and hormonal therapies for prostate cancer: A nested case–control study},
journal = {Fundamental & Clinical Pharmacology},
year = {2025},
doi = {10.1111/fcp.70004}
}
EUVIMED